Home
Courses
Features
PACULit Newsletter
PACUPrep
- PACUPrep MPJE
About Us
- Contact
Dashboard
Login

Home
Courses
Features
PACULit Newsletter
PACUPrep
- PACUPrep MPJE
About Us
- Contact
Dashboard
Login

Sign in Sign up

Pharmacy & Acute Care University

Search for:

Pharmacy & Acute Care University

Home
Courses
Features
PACULit Newsletter
PACUPrep
- PACUPrep MPJE
About Us
- Contact
Dashboard
Login

Search for:

PACULit Literature Updates September 2025: Oncology

0% Complete

0/0 Steps

Immune mediated adverse events in the randomized phase 3 TOPAZ 1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

1 Topic
|
1 Quiz
1. Immune mediated adverse events in the randomized phase 3 TOPAZ 1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
- Immune mediated adverse events in the randomized phase 3 TOPAZ 1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer Quiz
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma DREAMM7 updated overall survival analysis from a global randomised open label phase 3 trial

1 Topic
|
1 Quiz
1. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma DREAMM7 updated overall survival analysis from a global randomised open label phase 3 trial
- Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma DREAMM7 updated overall survival analysis from a global randomised open label phase 3 trial Quiz
PACULit Daily Literature Update: Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database

1 Topic
|
1 Quiz
1. PACULit Daily Literature Update: Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database
- PACULit Daily Literature Update: Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database Quiz
PACULit Daily Literature Update: Effects of BojungikkiTang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors a randomized pilot study

1 Topic
|
1 Quiz
1. PACULit Daily Literature Update: Effects of BojungikkiTang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors a randomized pilot study
- PACULit Daily Literature Update: Effects of BojungikkiTang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors a randomized pilot study Quiz
PACULit Daily Literature Update: Long acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine treated patients with indolent B cell non Hodgkin lymphoma a multicentric real life experience

1 Topic
|
1 Quiz
1. PACULit Daily Literature Update: Long acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine treated patients with indolent B cell non Hodgkin lymphoma a multicentric real life experience
- PACULit Daily Literature Update: Long acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine treated patients with indolent B cell non Hodgkin lymphoma a multicentric real life experience Quiz
First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC a single-arm phase II study

1 Topic
|
1 Quiz
1. First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC a single-arm phase II study
- First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC a single-arm phase II study Quiz
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma

1 Topic
|
1 Quiz
1. Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
- Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma Quiz
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

1 Topic
|
1 Quiz
1. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer Quiz
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure

1 Topic
|
1 Quiz
1. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
- Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure Quiz
Phase I II clinical trial on the safety and preliminary efficacy of donor derived anti leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation study rational and design

1 Topic
|
1 Quiz
1. Phase I II clinical trial on the safety and preliminary efficacy of donor derived anti leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation study rational and design
- Phase I II clinical trial on the safety and preliminary efficacy of donor derived anti leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation study rational and design Quiz
Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma subgroup analysis of the ECHELON2 study at 5 years followup

1 Topic
|
1 Quiz
1. Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma subgroup analysis of the ECHELON2 study at 5 years followup
- Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma subgroup analysis of the ECHELON2 study at 5 years followup Quiz
Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice A Brazilian Multicenter Study

1 Topic
|
1 Quiz
1. Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice A Brazilian Multicenter Study
- Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice A Brazilian Multicenter Study Quiz
Talquetamab improves patient reported symptoms and health related quality of life in relapsed or refractory multiple myeloma Results from the phase 12 MonumenTAL1 study

1 Topic
|
1 Quiz
1. Talquetamab improves patient reported symptoms and health related quality of life in relapsed or refractory multiple myeloma Results from the phase 12 MonumenTAL1 study
- Talquetamab improves patient reported symptoms and health related quality of life in relapsed or refractory multiple myeloma Results from the phase 12 MonumenTAL1 study Quiz
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

1 Topic
|
1 Quiz
1. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
- Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer Quiz
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial

1 Topic
|
1 Quiz
1. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial
- Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial Quiz
Real world patient profile and step up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database

1 Topic
|
1 Quiz
1. Real world patient profile and step up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database
- Real world patient profile and step up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database Quiz
Virtual reality for outpatient management of cancer pain a pilot dosing study

1 Topic
|
1 Quiz
1. Virtual reality for outpatient management of cancer pain a pilot dosing study
- Virtual reality for outpatient management of cancer pain a pilot dosing study Quiz
Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma

1 Topic
|
1 Quiz
1. Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma
- Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma Quiz
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors should we treat beyond two years

1 Topic
|
1 Quiz
1. Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors should we treat beyond two years
- Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors should we treat beyond two years Quiz
Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab

1 Topic
|
1 Quiz
1. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab
- Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab Quiz
ACPE Required Forms: PACULit Literature Updates September 2025: Oncology

3 Topics

Quizzes

PACULit Literature Updates September 2025: Oncology Quiz

Participants 440

Allison Clemens
April
ababaabhay
achoi2392
adhoward1

Show more

Quiz 20 of 21

← Previous Next→

Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab Quiz

PACULit Literature Updates September 2025: Oncology Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab Quiz

Time limit: 0

Quiz Summary

0 of 3 Questions completed

Questions:

Information

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You must first complete the following:

Results

Quiz complete. Results are being recorded.

Results

0 of 3 Questions answered correctly

Your time:

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

1
2
3

Current
Review
Answered
Correct
Incorrect

Question 1 of 3

1. Question
John is a 65-year-old male with metastatic non-small cell lung cancer (NSCLC) currently receiving nivolumab immunotherapy. He has a history of type 2 diabetes managed with metformin 1000 mg twice daily. He presents for a routine medication review and asks about the impact of his diabetes medication on his cancer treatment outcomes.

Question: Based on current evidence, what should the pharmacist counsel John regarding the effect of metformin on his overall survival while receiving nivolumab for metastatic NSCLC?
- Metformin use is associated with decreased overall survival and should be discontinued.
- Metformin has no impact on survival outcomes and can be continued without concern.
- Metformin use is associated with improved overall survival and may provide a benefit during nivolumab therapy.
- Metformin use increases progression-free survival but not overall survival.
Correct

Incorrect
Question 2 of 3

2. Question
Linda is a 70-year-old female with metastatic NSCLC and type 2 diabetes, treated with nivolumab and metformin 850 mg twice daily. She reports mild fatigue but no bleeding symptoms. Her recent labs show a platelet count trending downward but still within normal limits. She seeks advice on potential side effects of her medications.

Question: What is the most appropriate pharmacist recommendation regarding monitoring for adverse effects in Linda’s case?
- No additional monitoring is needed as metformin does not affect hematologic parameters.
- Advise routine platelet count monitoring due to increased risk of grade 3-4 thrombocytopenia with concurrent metformin and nivolumab use.
- Recommend discontinuing metformin immediately to prevent hematologic toxicity.
- Suggest switching nivolumab to an alternative immunotherapy to reduce toxicity risk.
Correct

Incorrect
Question 3 of 3

3. Question
Mark is a 62-year-old male with metastatic NSCLC on nivolumab therapy. He is also diabetic and on metformin 500 mg twice daily. His oncologist is considering extending nivolumab treatment cycles due to stable disease. Mark asks about the benefits and risks of prolonged nivolumab therapy in his context.

Question: What information should the pharmacist provide regarding the relationship between nivolumab treatment duration and mortality risk in patients like Mark?
- Longer nivolumab treatment cycles are associated with increased mortality risk and should be avoided.
- There is no relationship between nivolumab treatment duration and mortality risk.
- Increased number of nivolumab cycles is associated with reduced mortality risk, supporting prolonged treatment when tolerated.
- Nivolumab treatment duration should be limited to minimize risk of thrombocytopenia.
Correct

Incorrect